Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of posterior juxtascleral triamcinolone acetonide added to Visudyne photodynamic therapy for predominantly classic choroidal neovascularisation in age-related macular degeneration
2005-002466-11Phase 2Terminated
- Sponsor
- King's College Hospital
- Start
- Dec 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in age-related macular degeneration (AMD) and Subretinal neovascularization comparing Triamcinolone acetonide + verteporfin photodynamic therapy with Verteporfin photodynamic therapy alone (2 arms). Primary endpoint: Mean difference in letters lost from baseline visual acuity at 1 year between groups. Started Dec 2005; status: terminated.
02
Drugs
triamcinolone acetonideverteporfin
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on 2005-002466-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002466-11.